Why does one drug, Kaydeco, cost €232,000?
As more medicines costing hundreds of thousands of euro are launched, can the state afford to pay? And is Big Pharma pricing drugs fairly? Susan Mitchell reports.
It is one of the oldest debates in economics: what is the difference between what something costs and what it is worth? In Ireland, that debate has been given new urgency by Kalydeco, a drug used to treat cystic fibrosis.
Kalydeco is a revolutionary drug that will transform the lives of patients who have at least one copy of the G551D mutation - the so-called Celtic gene mutation.
The manufacturer, Vertex Pharmaceuticals, priced Kayldeco...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
*New subscribers only
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Quarterly
€55
€42
90 Day Pass
2 Yearly
€315
€248
Unlimited Access for 2 Years
Team Pass
Get a Business Account for you and your team
Related Stories
The year in review
The best writing and and the biggest stories of 2019 from the Business Post
Newsround: What Thursday’s papers say
Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals
More cycle routes, expansion of Luas to Bray and new bus network proposed
Greater Dublin Area draft Transport Strategy published
